Featured
Key Questions at the Heart of Inherited Retinal Disease Gene Therapy Innovation
Durability and inflammation are steering clinical trial development.
By Thomas A. Mendel, MD, PhD
Developmental Retinal Vascular Disorders
Familial exudative vitreoretinopathy, Norrie disease, and incontinentia pigmenti can be distinguished by systemic manifestations and genetic testing.
By Jay K. Rathinavelu, BSE, Lejla Vajzovic, MD, FASRS, Grant A. Justin, MD
A Basic Primer on Gene Therapy
New approaches currently under investigation may revolutionize treatment of blinding diseases.
By Thomas A. Ciulla, MD, MBA, Aumer Shughoury, MD
Gene Therapy for Dry AMD
Current trials are evaluating intervention using different vectors and delivery methods.
By Ehsan Rahimy, MD, Austen N. Knapp, MD
Update on Optogenetics for Advanced Retinal Degenerations
Several programs are under way.
By Joseph Martel, MD, Jose-Alain Sahel, MD
Current Challenges in Gene Therapy Trials
Managing inflammation is a hurdle that must be addressed.
By Glenn C. Yiu, MD, PhD, Arshad M. Khanani, MD, MA, Kathryn L. Pepple, MD, PhD
Departments
UPFRONT: Gene Therapy's Price Tag
By Peter K. Kaiser, MD
UVEITIS CORNER: Neoplastic Conditions Masquerading as Uveitis
Differential diagnosis is important in patients with uveitic symptoms.
By Kushal U. Agrawal, MS, Konica Singla, MD, Sruthi Arepalli, MD, et al.
NEW PRODUCT APPLICATIONS: Ranibizumab Biosimilar Offers Lower-price Treatment Option
Cimerli, a VEGF inhibitor, was recently approved to treat the same retina conditions as Lucentis.
By Karen Appold, contributing writer
News
SUBSPECIALTY NEWS: First drug approved for ROP, PDT laser approved, inequities in ophthalmology research, and more.
By Rochelle Nataloni, contributing writer